BIOS Health
AI-powered neural interfaces transforming chronic disease treatment globally.
Headquartered in Cambridge, UK, with a growing presence in North America, including a precision medicine center in California and partnerships across Europe and Canada.
Founding Story
Founded in 2015 by Cambridge University graduates Emil Hewage, a computational neuroscientist, and Oliver Armitage, a biomechanical engineer, BIOS Health emerged from a shared vision to harness the power of neural data to treat chronic diseases. Recognizing the untapped potential of the nervous system in managing health, they aimed to develop technologies that could read and write neural signals, leading to personalized and effective treatments.
The founders identified that many chronic conditions, such as heart failure and arthritis, are driven by faulty neural signals. By decoding these signals, they realized the possibility of correcting them in real-time, offering a new avenue for treatment that goes beyond traditional pharmaceuticals.
BIOS Health's early work focused on developing AI-powered neural interfaces capable of interpreting the complex language of the nervous system. Their technology demonstrated the ability to provide real-time insights into how pharmaceuticals affect neural activity, significantly reducing the time required to assess drug efficacy.
A significant milestone was the launch of a $21 million neural research project, expanding BIOS Health's technology into eight global clinics. This initiative validated their approach and showcased the scalability of their solutions in real-world clinical settings.
Core Technology
BIOS Health's core technology revolves around AI-powered neural interfaces that can both read and write neural signals. By leveraging machine learning algorithms trained on the world's largest proprietary neural dataset, their system translates the complex language of the nervous system into actionable insights. This enables real-time monitoring and modulation of neural activity, offering personalized treatment options for chronic diseases.
Impact to Date
BIOS Health is revolutionizing chronic disease management by enabling real-time, personalized treatments through AI-driven neural interfaces.
Impact Use Case #1: Transforming Heart Failure Treatment
In collaboration with hospitals and research centers across Europe and North America, BIOS Health’s neural interface technology is being used to address heart failure at its root cause—dysfunctional communication between the nervous system and cardiovascular system. By decoding and interpreting neural signals related to cardiac function, BIOS enables clinicians to detect irregularities and deliver personalized neuromodulation therapies that stabilize heart rhythms and support improved cardiac output. This novel approach not only enhances treatment precision but also reduces reliance on pharmaceutical interventions alone. Early clinical data has shown improved patient outcomes, lower recurrence of symptoms, and a measurable decrease in costly hospital readmissions, suggesting that neural monitoring may become a new frontline standard in cardiovascular care.
Impact Use Case #2: Advancing Neuro-Cardiology Research
In a groundbreaking CA$800,000 collaboration with Mila, McGill University, and Université de Montréal, BIOS Health is pioneering the development of AI-controlled closed-loop neuromodulation systems for cardiac care. These systems use BIOS’s proprietary algorithms to both monitor neural signals in real time and deliver corrective electrical stimulation to stabilize cardiac function. By continuously adapting to the patient’s physiological state, the system can dynamically adjust treatments without clinician input. This level of autonomy holds promise for treating chronic cardiovascular conditions such as arrhythmias and autonomic dysfunction. The partnership also serves as a model for academic-industry collaboration, accelerating the translation of advanced AI research into real-world, life-saving technologies.
Impact Use Case #3: Enhancing Remote Patient Monitoring
BIOS Health’s Remote Health Platform empowers clinicians to maintain continuity of care for patients living with chronic diseases, even outside traditional clinical environments. By passively collecting data from wearable devices—such as neural activity, movement patterns, heart rate, and sleep quality—the platform constructs a rich, longitudinal health profile that updates in real time. This allows care teams to detect subtle changes that precede clinical deterioration and intervene earlier than would otherwise be possible. It also enables more adaptive and patient-specific treatment plans, significantly improving adherence and long-term outcomes. For patients, this brings a sense of agency and reassurance that they are being actively supported between visits, reducing anxiety and improving engagement in their care journey.
Impact Use Case #4: Optimizing Drug Efficacy Assessments
Traditional drug development processes often take years to validate therapeutic effects, with limited feedback during early phases. BIOS Health is changing that with neural biomarkers and AI tools that track the physiological response to medications in real time. By directly monitoring neural signaling pathways affected by a drug, BIOS can determine its efficacy minutes after administration—identifying whether the intervention is having the intended effect or causing unintended disruptions. This capability dramatically accelerates clinical trials and enables personalized dosing adjustments, especially in conditions where nervous system feedback is crucial, like chronic pain or autoimmune disorders. The result is faster drug development timelines, reduced risk for patients, and an entirely new paradigm in precision pharmacology.
.webp)
